Companies · Other Health Care

Saranas Inc.

HOUSTON · Other Health Care

Diligence memoA one-page analyst read on Saranas Inc. — recommendation, valuation, rhythm, risks.
$29.2M
Total raised · real
6
Rounds
9.4×
Latest step-up
Top 13%
Sector rank · raised
Series B
Latest stage · inferred · Fri Jul 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Saranas Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.67× the median modeled value of Series B Other Health Care companies in 2019–2021 (78 peers) — value vs value, same stage and era.
Dormant
  • Last raise 5.0 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

Saranas Inc. is one of 5376 Other Health Care companies tracked from HOUSTON. By capital raised it ranks in the upper tier (ahead of 88% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
65
Investors (latest)
2021-07-16
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2015-06-05 Raised $4.5M (real) Modeled valuation $91M (est)Series A2015Pre-Seed · 2016-03-18 Raised $725K (real) Modeled valuation $22M (est)Pre-Seed2016Series A · 2016-03-18 Raised $1.4M (real) Modeled valuation $29M (est)Series A2016Series A · 2017-04-25 Raised $3.3M (real) Modeled valuation $67M (est)Series A2017Series A · 2018-05-15 Raised $2.8M (real) Modeled valuation $57M (est)Series A2018Series A · 2020-04-28 Raised $1.7M (real) Modeled valuation $33M (est)Series A2020Series B · 2021-07-16 Raised $15M (real) Modeled valuation $250M (est)Series B2021+$725K+$1.4M+$3.3M+$2.8M+$1.7M+$15MCumulative $30M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$4.5M · 2015
Bridge · Series A-stage$725K · 2016smaller follow-on
Series A extension$1.4M · 2016
Series A extension$3.3M · 2017
Series A extension$2.8M · 2018
Series A extension$1.7M · 2020
Series B$15.5M · 2021

Stages are modeled from round size (public records carry no series label). No record for: Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 75%.

Modeled valuation trajectory
$249.6M
Base estimate est.
$36.4M
Conservative case
$787.1M
Upside case
$86.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series A · modeled $90.8M · 2015-06-052015Pre-Seed · modeled $22.3M · 2016-03-18Series A · modeled $28.8M · 2016-03-18Series A · modeled $66.8M · 2017-04-25Series A · modeled $56.5M · 2018-05-15Series A · modeled $33.4M · 2020-04-28Series B · modeled $249.6M · 2021-07-162021
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
64%
Survival probability
42% low · 78% high
1.36×/yr
Annual markup
1.64×/yr upside case
5.0 yr
Elapsed time used
5.0 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
12 mo
Avg between rounds
$4.8M/yr
Capital velocity
11.1 yr
On record since
2015
First round
7
Rounds on file
How it compares to the market

Benchmarked against 5376 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 12× above median
This company$29.2M
Sector median$2.4M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.9× of median
This company$15.5M
Sector median$17.8M
Modeled value — vs sector median (estimate, all stages) 11× above median
This company$249.6M
Sector median$22.1M

Raised more than 88% of sector peers (real $). Modeled value above 90% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #57 of 78.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)KSMS Holdings, LLC · Series B Raised $40.0M · modeled $885.1M (est)Infab HoldCo, Inc. · Series B Raised $36.5M · modeled $807.5M (est)Aquity Holdings, Inc. · Series B Raised $36.0M · modeled $797.6M (est)MHH Management Holdco, LLC · Series B Raised $35.1M · modeled $777.6M (est)Earli Inc. · Series B Raised $40.0M · modeled $756.4M (est)Encore Dermatology, Inc. · Series B Raised $89.6M · modeled $729.9M (est)National Spine & Pain Centers Holdings, LLC · Series B Raised $32.0M · modeled $708.9M (est)In Vitro Sciences, LLC · Series B Raised $31.5M · modeled $697.9M (est)Lotus Parent, Inc. · Series B Raised $31.2M · modeled $690.4M (est)Iron Oak Holdings LLC · Series B Raised $30.0M · modeled $664.6M (est)Squid Ink, Inc. · Series B Raised $30.2M · modeled $620.8M (est)Predict Innovation Investors, Llc · Series B Raised $27.9M · modeled $617.4M (est)Saranas Inc. (this company) Raised $29.2M · modeled $249.6M (est)Saranas Inc.
CompanyStageRaised · realValue · estvs peer med.
KSMS Holdings, LLCSeries B$40.0M$885.1M2.37×
Infab HoldCo, Inc.Series B$36.5M$807.5M2.16×
Aquity Holdings, Inc.Series B$36.0M$797.6M2.13×
MHH Management Holdco, LLCSeries B$35.1M$777.6M2.08×
Earli Inc.Series B$40.0M$756.4M2.02×
Encore Dermatology, Inc.Series B$89.6M$729.9M1.95×
National Spine & Pain Centers Holdings, LLCSeries B$32.0M$708.9M1.90×
In Vitro Sciences, LLCSeries B$31.5M$697.9M1.87×
Lotus Parent, Inc.Series B$31.2M$690.4M1.85×
Iron Oak Holdings LLCSeries B$30.0M$664.6M1.78×
Squid Ink, Inc.Series B$30.2M$620.8M1.66×
Predict Innovation Investors, LlcSeries B$27.9M$617.4M1.65×
Saranas Inc. this companySeries B$29.2M$249.6M0.67×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$4.5M2015-06-05$20.5M$90.8M85%
Pre-Seed$725K2016-03-18$4.0M$22.3M85%
Series A$1.4M2016-03-18$6.5M$28.8M85%
Series A$3.3M2017-04-25$15.0M$66.8M90%
Series A$2.8M2018-05-15$12.7M$56.5M90%
Series A$1.7M2020-04-28$7.5M$33.4M90%
Series B$15.5M2021-07-16$86.0M$249.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$4.5M2015-06-05
    • First recorded raise — entered as Series A.
    • 17 investors on this round.
  2. Pre-Seed$725K2016-03-18
    • Raised 9 mo later, in step with the ~14 mo sector norm.
    • Round 6.2× smaller than the prior — bridge or down round.
    • 9 investors on this round.
  3. Series A$1.4M2016-03-18
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.0× larger than the prior — scaling up.
    • 14 investors on this round.
  4. Series A$3.3M2017-04-25
    • Raised 13 mo later, in step with the ~14 mo sector norm.
    • Round 2.3× larger than the prior — scaling up.
    • 28 investors on this round.
  5. Series A$2.8M2018-05-15
    • Raised 13 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 32 investors on this round.
  6. Series A$1.7M2020-04-28
    • Raised again after 23 mo — slower than the ~14 mo sector norm.
    • Round 1.7× smaller than the prior — bridge or down round.
    • 39 investors on this round.
  7. Series B$15.5M2021-07-16
    • Raised 15 mo later, in step with the ~14 mo sector norm.
    • Round 9.4× larger than the prior — scaling up.
    • 65 investors on this round.
Intelligence
2022 ~Q3
Modeled next raise · ~12mo cadence
$46.5M
Modeled next size est.range $30.2M$74.3M
9.4×
Last step-up
$4.8M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Brian R. Smith20 other2021-07
Daniel Hawkins3 other2020-04
Larry Lawson3 other2016-03
James Reinstein2 other2020-04
John Huff1 other2020-04
Milton M. Morris1 other2015-06
Milton Morris1 other2016-03
Amy Kobe2021-07
Daniel M. Steppe2015-06
Daniel R. Hawkins2021-07
Dan Wolterman2021-07
Gill M. Jack2015-06
Jack Gill2016-03
Kevin Maples2018-05
Maples Kevin2017-04
Mehdi Razavi2015-06
Michael Magnani2015-06
Zaffer Syed2017-04
Registry & provenance

Saranas Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1615461
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
VahatiCor, Inc.Other Health CareSeries B$21.2M$91.6Mnetwork1 shared operator · same sector · same stage
Levita Magnetics International Corp.Other Health CareSeries B$20.1M$274.6Mnetwork1 shared operator · same sector · same stage
TVA Medical, Inc.Other Health CareSeries B$15.3M$338.4Mnetwork1 shared operator · same sector · same stage
Accure Acne, Inc.Other Health CareSeries B$28.9M$214.4Msame sector · same stage
Seniorlink IncOther Health CareSeries B$30.0M$221.5Msame sector · same stage
ASC San Rafael LLCOther Health CareSeries B$28.3M$294.9Msame sector · same stage
Eyenuk, Inc.Other Health CareSeries B$28.3M$262.6Msame sector · same stage
Edgewood OpCo, LLCOther Health CareSeries B$28.0M$177.4Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Carena IncOther Health CareSeries A$121.1M85%
Sunniva Inc.Other Health CareSeries A$121.1M84%
Imagen Fojas Support Services, LLCOther Health CarePre-Seed$4.5M83%
Spesana Inc.Other Health CareSeed$2.8M83%
AVAVA, Inc.Other Health CareSeries B$77.9M82%
SegAna, Inc.Other Health CarePre-Seed$5.5M82%
CannAssist International CorpOther Health CarePre-Seed$4.6M82%
Eisana CorpOther Health CareSeed$22.4M82%
Frequently asked
How much funding has Saranas Inc. raised?
Saranas Inc. has raised approximately $29.2M in disclosed capital across 6 recorded financing rounds, aggregated from public filings.
What is Saranas Inc.'s estimated valuation?
Provath's modeled valuation for Saranas Inc. is approximately $249.6M (modeled range $36.4M–$787.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Saranas Inc. at?
Saranas Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Fri Jul 16.
What does Saranas Inc. do and where is it based?
Saranas Inc. operates in the Other Health Care sector, based in HOUSTON.
Explore related

See where Saranas Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Saranas Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.